Nevisense selected for ‘SpotCheck’ remote melanoma detection evaluation study by The Ronald O. Perelman Department of Dermatology at NYU Langone Health
Stockholm, Sweden and New York, USA - August 18, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that Nevisense will be included in a large clinical study initiated by The Ronald O. Perelman Department of Dermatology clinic at NYU Langone Health. The SpotCheck study will investigate the use of Nevisense as a point-of-care diagnostic tool to assist with skin cancer detection in a remote setting such as a non-specialist practice or pharmacy. The study will